1092939-16-6 Usage
General Description
"(betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile sulfate" is a chemical compound with potential biological and pharmaceutical applications. It consists of a cyclopentyl group, a pyrrolopyrimidinyl group, a pyrazole group, and a propanenitrile group, all linked together and in a sulfate salt form. (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile sulfate may be of interest in the development of new drugs for the treatment of various diseases, as it exhibits unique structural and functional properties that may be beneficial for targeting specific proteins or pathways. Further research and testing are needed to fully understand the potential uses and effects of this compound.
Check Digit Verification of cas no
The CAS Registry Mumber 1092939-16-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,2,9,3 and 9 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1092939-16:
(9*1)+(8*0)+(7*9)+(6*2)+(5*9)+(4*3)+(3*9)+(2*1)+(1*6)=176
176 % 10 = 6
So 1092939-16-6 is a valid CAS Registry Number.
1092939-16-6Relevant articles and documents
JAK PI3K/mTOR combination therapy
-
Page/Page column 23; 24, (2016/06/28)
Provided herein is a combination therapy comprising a JAK kinase inhibitor and a dual PI3K/mTOR inhibitor, as well as methods of treating various cancers through the use of such a combination therapy.
SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
-
Page/Page column 6, (2009/01/24)
The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
